KEAP1 and neoplasm: The inactivating mutations in KEAP1 and LKB1, as well as the activation of the YAP1 and/or RSK-mTOR pathway, contribute to mutant KRAS independency in tumor cells, potentially causing therapeutic resistance to KRAS inhibitors [43].